CSL says its CSL112 did not meet the primary efficacy endpoint in the Phase 3 AEGIS-II trial evaluating the highly-anticipated cholesterol efflux enhancer in reducing the risk of major adverse cardiovascular events. …
Disappointment as CSL's leading heart candidate misses in clinical trial
February 13, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Novartis partners with Advara HeartCare and TerryWhite Chemmart to launch Heart Health Collective,
December 6, 2024 - - Latest News -
Pfizer Australia launches Innovate Reconciliation Action Plan to advance equitable access to health and wellbeing
December 6, 2024 - - BioPharma -
Former CSL CEO Paul Perreault appointed strategic adviser to Microbio
December 5, 2024 - - Latest News -
More evidence backs the use of weight-loss therapies
December 5, 2024 - - Latest News -
ChatGPT would have produced more human responses than these committees
December 5, 2024 - - Latest News -
Anatara provides irritable bowel syndrome clinical trial update
December 4, 2024 - - Australian Biotech -
Digital health company Adherium secures R&D loan facility
December 4, 2024 - - Australian Biotech